Neurogenesis is a subject of intense interest and extensive research, but it stands at the center of a bitter debate over ethical and practical problems. Neurodegenerative diseases, such as Alzheimer's disease (AD), accompanied by a shifting balance between neurogenesis and neurodegeneration, are suitable for stimulation of neurogenesis for the benefit of diseased patients. We have previously shown that Abs against the EFRH sequence of -amyloid peptide (AP) prevent aggregation and disaggregate AP both in vitro and in vivo. EFRH, located in the soluble tail of the N-terminal region, acts as a regulatory site controlling both solubilization and disaggregation processes in the AP molecule. Here we show that anti-EFRH immunotherapy of a platelet-derived amyloid precursor protein transgenic mouse model of AD stimulates endogenous neurogenesis, suggested by elevated numbers of BrdU-incorporated cells, most of which are colocalized with a marker of mature neurons, NeuN. These newly born neurons expressed the activitydependent gene Zif268, indicating their functional integration and participation in response to synaptic input in the brain. These findings suggest that anti-amyloid immunotherapy may promote recovery from AD or other diseases related to AP overproduction and neurotoxicity by restoring neuronal population, as well as cognitive functions in treated patients.amyloid  ͉ immunotherapy ͉ neurodegenerative diseases ͉ platelet-derived amyloid precursor protein transgenic mice A dult brain neurogenesis continues throughout life, helping to maintain nervous-system integrity. It involves neural stem cells (NSC) found in the two principal neurogenic regions: the subgranular zone (SGZ) of the dentate gyrus (DG), which generates the hippocampal interneurons (1), and the forebrain subventricular zone (SVZ) of the lateral ventricles, which migrate to the olfactory bulb (2-5). NSC are self-renewing, multipotent cells that generate neurons, astrocytes, and oligodendrocytes in the nervous system. These progenitor cells migrate to their final locations and functions, becoming neurons or glia depending on their microenvironment (reviewed in ref. 6). Alterations in the microenvironment may affect neurogenesis, rendering it ectopic or even blocked, thus leading to deficits in learning and memory (7-9).One of the major pathological features of the Alzheimer's disease (AD) patient's brain tissue is the abundance of amyloid plaques, composed of -amyloid peptide (AP) (10). The amyloid cascade hypothesis states that overproduction of AP, or failure to clear it, leads to AD primarily through amyloid deposition associated with cell death, which is reflected in memory impairment (11,12).During the last decade, anti-AP immunization proved effective in amyloid burden reduction and improvement of memory deficits in AD transgenic (Tg) mice (13,14) and in AD patients (15). A few main mechanisms are considered to be involved in immunotherapy efficacy: catalytic dissolution of A fibrils (16); opsonization of amyloid by the Ab and su...